DEMARCO v. FARMACEUTICALRX, LLC

CourtDistrict Court, W.D. Pennsylvania
DecidedMarch 7, 2023
Docket2:22-cv-01164
StatusUnknown

This text of DEMARCO v. FARMACEUTICALRX, LLC (DEMARCO v. FARMACEUTICALRX, LLC) is published on Counsel Stack Legal Research, covering District Court, W.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
DEMARCO v. FARMACEUTICALRX, LLC, (W.D. Pa. 2023).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF PENNSYLVANIA

BRIAN DEMARCO, et al, Plaintiffs, Civil Action No. 2:22-cv-1164 Vv. Hon. William S. Stickman [V FARMACEUTICALRX, LLC, et al, Defendants.

~ MEMORANDUM OPINION WILLIAM S. STICKMAN IV, United States District Judge Plaintiffs Brian DeMarco, Clint Goodenow, Mark Williams, Jason Hummel, and Alex Fitzgerald filed an Amended Complaint and Demand for Jury Trial (“Amended Complaint”) against Defendants! FarmaceuticalRX, LLC; FRX Management Holdings, LLC; FRX Growth Partners, LLC; Rebecca L. Myers (“Myers”); Dietrich A. Stephan (“Stephan”); and Joy E. Bochner (“Bochner”). (ECF No. 10). At Count I and Count III, Plaintiffs bring claims for violations of the Fair Labor Standards Act (“FLSA”), 29 U.S.C. § 207. Ud). At Count II, Plaintiffs bring a claim for violation of the Pennsylvania Minimum Wage Act (““PMWA”), 43 Pa. Stat. Ann. § 333.104. (id.). Plaintiffs allege that Defendants failed to pay them adequate overtime compensation in violation of the FLSA (Count I) and PMWA (Count IJ) and that Defendants “constructively discharged” them in retaliation for their complaints about Defendants’ alleged FLSA and PMWA violations (Count III). Presently before the Court is Defendants’ Motion to Dismiss Plaintiffs’

' Plaintiffs stipulated to the dismissal with prejudice of Defendants FRX Growth, LLC; FarmaceuticalRX Real Estate Pennsylvania, LLC; and FarmaceuticalRX GP of Pennsylvania, LLC (ECF No. 15), which the Court approved. (ECF No. 20).

Amended Complaint Pursuant to Federal Rule of Civil Procedure 12(b)(6).* (ECF No. 16). For the reasons set forth below, Defendants’ Motion to Dismiss Plaintiffs’ Amended Complaint will be denied. I. FACTUAL BACKGROUND FarmaceuticalR xX, LLC; FRX Management Holdings, LLC; and FRX Growth Partners, LLC (collectively “Corporate Defendants”) are medical marijuana growing and processing companies licensed by the Commonwealth of Pennsylvania and the State of Ohio. (ECF No. 10, { 29). Corporate Defendants each have the same principal place of business at 660 Martin Luther King Jr. Boulevard, Farrell, Pennsylvania 16121. Ud. §{ 6-8). Myers, Stephan, and Bochner (collectively “Individual Defendants”) each seemingly own a portion of Corporate Defendants and serve on Corporate Defendants’ Board of Directors. (Ud. 13-15). Additionally, Myers is Corporate Defendants’ Chief Executive Officer (“CEO”); Stephan is Corporate Defendants’ Chief Science Officer; and Bochner is Corporate Defendants’ Director of Health and Wellness. Ud.). Plaintiffs allege that Individual Defendants each “supervised, exercised control over, and [were] responsible for the FLSA/PMWA violations and misclassification at issue in this case.” (d.). Plaintiffs worked as delivery drivers and were responsible for transporting Corporate Defendants’ medical marijuana products from their facility in Farrell, Pennsylvania to licensed dispensaries in Pennsylvania. (Ud. § 32).

* Defendants uploaded the incorrect PDF version of their motion to dismiss, which sought the dismissal of the claims against FRX Growth Partners, LLC, Myers, Stephan, and Bochner. (ECF No. 16). Defendants subsequently filed an errata that joined FarmaceuticalRX, LLC and FRX Management Holdings, LLC to the motion to dismiss. (ECF No. 18). Plaintiffs argue that Defendants intended to file the original motion to dismiss as written and the errata was filed for the purpose of delaying the case. (See ECF No. 23, p. 3). Defendants will be afforded the benefit of the doubt and the Court will address their motion to dismiss the claims against all remaining defendants.

Plaintiffs were hired by Defendants “on an ongoing basis for a period of years of indefinite duration;” used Defendants’ vehicles and equipment for transporting Defendants’ products; and were covered by Defendants’ insurance policies when providing transportation services for Defendants. (/d. § 33). “Plaintiffs received paychecks and tax forms from FarmaceuticalRX, LLC and FRX Management Holdings, LLC.” (Ud. § 26). According to Plaintiffs, Defendants had complete control over all aspects of Plaintiffs’ work, including their work schedules. (/d. § 33). Defendants classified Plaintiffs as independent contractors, and, as a result, did not pay Plaintiffs overtime compensation when they worked over 40 hours in a week. (Ud. ¥ 34). Plaintiffs contend that, under the FLSA and PMWA, they should have been classified as “employees” of Corporate Defendants—each of which, according to Plaintiffs, “collectively constitute a Single and/or Joint Employer.” Ud. 18, 33). In the early stages of performing transportation services for Defendants, “Plaintiffs regularly complained to Defendants about their misclassification as independent contractors and the failure to pay them overtime compensation.” (/d. § 36). According to Plaintiffs, Defendants made promises to correct Plaintiffs’ alleged misclassification, but never did so. (Ud 4 37). Plaintiffs allege that “Defendants claimed that they could not correct the misclassification and overtime issues mid-year because it would look suspicious and would trigger an audit of Defendants’ books by the Internal Revenue Service.” (Ud. § 38). This issue was the subject of “extensive meetings over an extended period among Defendants’ senior-level management, owners, and officers.’ (Ud § 39). Plaintiffs continued to complain about their alleged misclassification and resulting lack of overtime compensation. (Ud. §/ 40). In early May 2022, “Defendants held a meeting in which Plaintiffs were informed that, if they wanted to continue working for Defendants, they were required to ‘reapply’ for employment as W-2 employees” at

reduced wage rates. (Id. J 41). According to Plaintiffs, Defendants had already sought out Plaintiffs’ replacements before the May 2022 meeting. (Ud. § 42). II. LEGAL STANDARD A motion to dismiss filed under Federal Rule of Civil Procedure (“Rule”) 12(b)(6) tests the legal sufficiency of the complaint. Kost v. Kozakiewicz, 1 F.3d 176, 183 (3d Cir. 1993). A plaintiff must allege sufficient facts that, if accepted as true, state a claim for relief plausible on its face. See Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007); see also Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). A court must accept all well-pleaded factual allegations as true and view them in the light most favorable to a plaintiff. See Doe v. Princeton Univ., 30 F.4th 335, 340 (3d Cir. 2022); see also Fowler v. UPMC Shadyside, 578 F.3d 203, 210 (3d Cir. 2009). Although a court must accept the allegations in the complaint as true, it is “not compelled to accept unsupported conclusions and unwarranted inferences, or a legal conclusion couched as a factual allegation.” Baraka v. McGreevey, 481 F.3d 187, 195 (3d Cir. 2007) (citations omitted). The “plausibility” standard required for a complaint to survive a motion to dismiss is not akin to a “probability” requirement but asks for more than sheer “possibility.” Jgbal, 556 U.S. at 678 (citing Twombly, 550 U.S. at 556). In other words, the complaint’s factual allegations must be enough to raise a right to relief above the speculative level, on the assumption that all the allegations are true even if doubtful in fact.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Rutherford Food Corp. v. McComb
331 U.S. 722 (Supreme Court, 1947)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Kost v. Kozakiewicz
1 F.3d 176 (Third Circuit, 1993)
Norma J. Nesbit v. Gears Unlimited, Inc
347 F.3d 72 (Third Circuit, 2003)
Fowler v. UPMC SHADYSIDE
578 F.3d 203 (Third Circuit, 2009)
Commonwealth v. Stuber
859 A.2d 1253 (Supreme Court of Pennsylvania, 2004)
Bamgbose v. Delta-T Group, Inc.
684 F. Supp. 2d 660 (E.D. Pennsylvania, 2010)
Davis v. Abington Memorial Hospital
817 F. Supp. 2d 556 (E.D. Pennsylvania, 2011)
COM., DEPT. OF LABOR AND INDUSTRY v. Stuber
822 A.2d 870 (Commonwealth Court of Pennsylvania, 2003)
Myers v. Garfield & Johnson Enterprises, Inc.
679 F. Supp. 2d 598 (E.D. Pennsylvania, 2010)
Thompson v. US Airways, Inc.
717 F. Supp. 2d 468 (E.D. Pennsylvania, 2010)
Patricia Thompson v. Real Estate Mortgage Network
748 F.3d 142 (Third Circuit, 2014)
Graves v. Lowery
117 F.3d 723 (Third Circuit, 1997)
Baraka v. McGreevey
481 F.3d 187 (Third Circuit, 2007)
Darryl Williams v. Jani King of Philadelphia Inc
837 F.3d 314 (Third Circuit, 2016)
Priya Verma v. 3001 Castor Inc
937 F.3d 221 (Third Circuit, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
DEMARCO v. FARMACEUTICALRX, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/demarco-v-farmaceuticalrx-llc-pawd-2023.